请输入关键字
请输入关键字
订购
*国家
中国
美国
中国香港
中国澳门
中国台湾
阿尔巴尼亚
阿尔及利亚
阿根廷
阿拉伯联合酋长国
阿鲁巴
阿曼
阿塞拜疆
阿森松岛
埃及
埃塞俄比亚
爱尔兰
爱沙尼亚
安道尔
安哥拉
安圭拉
安提瓜和巴布达
奥地利
奥兰群岛
澳大利亚
巴巴多斯
巴布亚新几内亚
巴哈马
巴基斯坦
巴拉圭
巴勒斯坦领土
巴林
巴拿马
巴西
白俄罗斯
百慕大
保加利亚
北马里亚纳群岛
贝宁
比利时
冰岛
波多黎各
波兰
波斯尼亚和黑塞哥维那
玻利维亚
伯利兹
博茨瓦纳
不丹
布基纳法索
布隆迪
朝鲜
赤道几内亚
丹麦
德国
迪戈加西亚岛
东帝汶
多哥
多米尼加共和国
多米尼克
俄罗斯
厄瓜多尔
厄立特里亚
法国
法罗群岛
法属波利尼西亚
法属圭亚那
法属南部领地
梵蒂冈
菲律宾
斐济
芬兰
佛得角
福克兰群岛
冈比亚
刚果(布)
刚果(金)
哥伦比亚
哥斯达黎加
格恩西岛
格林纳达
格陵兰
格鲁吉亚
古巴
瓜德罗普
关岛
圭亚那
哈萨克斯坦
海地
韩国
荷兰
荷属加勒比区
荷属圣马丁
黑山
洪都拉斯
基里巴斯
吉布提
吉尔吉斯斯坦
几内亚
几内亚比绍
加拿大
加纳
加纳利群岛
加蓬
柬埔寨
捷克
津巴布韦
喀麦隆
卡塔尔
开曼群岛
科科斯(基林)群岛
科摩罗
科索沃
科特迪瓦
科威特
克罗地亚
肯尼亚
库克群岛
库拉索
拉脱维亚
莱索托
老挝
黎巴嫩
立陶宛
利比里亚
利比亚
联合国
列支敦士登
留尼汪
卢森堡
卢旺达
罗马尼亚
马达加斯加
马恩岛
马尔代夫
马耳他
马拉维
马来西亚
马里
马其顿
马绍尔群岛
马提尼克
马约特
毛里求斯
毛里塔尼亚
美国本土外小岛屿
美属萨摩亚
美属维尔京群岛
蒙古
蒙特塞拉特
孟加拉国
秘鲁
密克罗尼西亚
缅甸
摩尔多瓦
摩洛哥
摩纳哥
莫桑比克
墨西哥
纳米比亚
南非
南极洲
南乔治亚和南桑威奇群岛
南苏丹
瑙鲁
尼加拉瓜
尼泊尔
尼日尔
尼日利亚
纽埃
挪威
诺福克岛
帕劳
皮特凯恩群岛
葡萄牙
日本
瑞典
瑞士
萨尔瓦多
萨摩亚
塞尔维亚
塞拉利昂
塞内加尔
塞浦路斯
塞舌尔
沙特阿拉伯
圣巴泰勒米
圣诞岛
圣多美和普林西比
圣赫勒拿
圣基茨和尼维斯
圣卢西亚
圣马丁岛
圣马力诺
圣皮埃尔和密克隆群岛
圣文森特和格林纳丁斯
斯里兰卡
斯洛伐克
斯洛文尼亚
斯瓦尔巴和扬马延
斯威士兰
苏丹
苏里南
所罗门群岛
索马里
塔吉克斯坦
泰国
坦桑尼亚
汤加
特克斯和凯科斯群岛
特里斯坦-达库尼亚群岛
特立尼达和多巴哥
突尼斯
图瓦卢
土耳其
土库曼斯坦
托克劳
瓦利斯和富图纳
瓦努阿图
危地马拉
委内瑞拉
文莱
乌干达
乌克兰
乌拉圭
乌兹别克斯坦
希腊
西班牙
西撒哈拉
新加坡
新喀里多尼亚
新西兰
匈牙利
休达及梅利利亚
叙利亚
牙买加
亚美尼亚
也门
伊拉克
伊朗
以色列
意大利
印度
印度尼西亚
英国
英属维尔京群岛
英属印度洋领地
约旦
越南
赞比亚
泽西岛
乍得
直布罗陀
智利
中非共和国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-hIGHA1/hCD89 mice
Strain Name
C57BL/6N-tm1(IGHA1)BcgenGt(ROSA)26Sortm1(CD11b-FCAR)Bcgen/Bcgen
Common Name  B-hIGHA1/hCD89 mice
Background C57BL/6N Catalog number 112799
Aliases  IGHA1 (IgA1);
CD89 (FcalphaRI; CTB-61M7.2, FCAR, Fc fragment of IgA receptor)
Protein expression analysis in T, B cells

from clipboard



CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was mildly detectable in T and B cells in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 



Protein expression analysis in serum


from clipboard

Strain specific IgA expression analysis in homozygous B-hIGHA1/hCD89 mice by ELISA. Serum were collected from 8-weeks wild-type mice C57BL/6 mice (+/+) and 8-weeks homozygous B-hIGHA1/hCD89 mice (H/H, H/+ or H/H, H/H), and analyzed by ELISA with species-specific IgA ELISA kit. hIgA was exclusively detectable in homozygous mice, but soluble IgA  levels were higher in B-hIGHA1/hCD89 mice (H/H, H/+) compared to that in B-hIGHA1/hCD89 mice (H/H, H/H).



Protein expression analysis in NK cells and DCs

from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was detectable in NK cells and DCs in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Protein expression analysis in monocytes and macrophages

from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was detectable in monocytes and macrophages in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Protein expression analysis in neutrophils

from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was detectable in neutrophils in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Protein expression analysis in spleen

from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was mainly detectable in NK cells, DCs, monocytes, macrophages and neutrophils in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Analysis of leukocytes cell subpopulation in spleen

from clipboard


Analysis of spleen leukocyte subpopulations by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of B cells was decreased and T cells increased in B-hIGHA1/hCD89 mice accompanied with a smaller spleen compared to that in C57BL/6 mice. Values are expressed as mean ± SD.

Protein expression analysis in T, B cells

from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Bone marrow cells were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was detectable in T and B cells in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Protein expression analysis in NK cells and DCs

from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Bone marrow cells were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was detectable in NK cells and DCs in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Protein expression analysis in monocytes and macrophages

from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Bone marrow cells were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was detectable in monocytes and macrophages in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Protein expression analysis in neutrophils


from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Bone marrow cells were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was detectable in neutrophils in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Protein expression analysis in Bone marrow

from clipboard


CD89 protein expression analysis in heterozygous and homozygous B-hIGHA1/hCD89 mice by flow cytometry. Bone marrow cells were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H), and then analyzed by flow cytometry with anti-hCD89 antibody. hCD89 was detectable in T, B, NK cells, DCs, monocytes, macrophages and neutrophils in B-hIGHA1/hCD89 mice (H/H, H/+) and B-hIGHA1/hCD89 mice (H/H, H/H). 

Analysis of leukocytes cell subpopulation in bone marrow

from clipboard


Analysis of bone marrow leukocyte subpopulations by flow cytometry. Bone marrow cells were collected from wild-type C57BL/6 mice (+/+), heterozygous B-hIGHA1/hCD89 mice (H/H, H/+) and homozygous B-hIGHA1/hCD89 mice (H/H, H/H). Flow cytometry analysis of the bone marrow cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of B cells was decreased in B-hIGHA1/hCD89 mice compared to that in C57BL/6 mice. Values are expressed as mean ± SD.

Analysis of blood and urine

from clipboard

Blood and urine analysis: Four 30-weeks-old male B-hIGHA1/hCD89 mice(H/H,H/H) and C57BL/6N were selected to assess the blood and urine indicators. The results showed that the levels of creatinine (CREA) and urine protein in the urine, as well as blood urea nitrogen (UREA) and creatinine (CREA), did not show significant differences compared to wild mice.


Analysis of kidney tissue sections

from clipboard

Analysis of kidney tissue sections: Four 30-week-old male B-hIGHA1/hCD89 mice(H/H,H/H) and C57BL/6N were selected for kidney tissue section immunohistochemical staining analysis. The results showed a slight increase in CD11b staining in the B-hIGHA1/hCD89 mice(H/H,H/H), while IgA and C3 staining showed no significant differences between B-hIGHA1/hCD89 mice(H/H,H/H) and C57BL/6N.


FAQ

1. Q: Why do the results show that the serum IgA levels are lower in CD89 homozygous mice compared to CD89 heterozygous mice? 
    A: It is speculated that the increase in hCD89 expression may lead to a higher occurrence of IgA-sCD89 complexes, resulting in reduced serum hIgA levels.
2. Q: Have the expression profiles of IgA and CD89 been assessed? 
    A: We are about to conduct this detection using newborn mice (born on August 18).
3. Q: Is Gd-IgA present in the mice?  
    A: We will also check whether Gd-IgA is present in the serum of the newborn mice.
4. Q: Have the T cell and B cell populations in these mice been affected?
    A: We will also perform T and B cell phenotype analysis using the newborn mice.
5. Q: This mouse does not have the IgAN phenotype. What is your next development plan?
    A: The lack of phenotype in this mice may be due to low hCD89 expression levels and inconsistencies with the expression profile reported in the literature, as well as relatively low serum IgA levels. Therefore, we have developed a new mouse modle, anticipating that both hCD89 and hIgA expression levels can be improved. We expect to have heterozygous mice born in January 2025, and we plan to perform phenotype validation once the mice reach 12 weeks of age. We anticipate new progress in May 2025, and we appreciate your patience.
6. Q: Is induction required during the mouse breeding process?
    A: No, it is not necessary. The article shows that α1KI-CD89 mice raised in an SPF environment can develop the disease by 12 weeks of age..